Compare GKOS & UHS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GKOS | UHS |
|---|---|---|
| Founded | 1998 | 1978 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Hospital/Nursing Management |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.9B | 10.2B |
| IPO Year | 2015 | 1994 |
| Metric | GKOS | UHS |
|---|---|---|
| Price | $177.33 | $169.69 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 12 | 11 |
| Target Price | $126.92 | ★ $216.36 |
| AVG Volume (30 Days) | ★ 580.7K | 554.8K |
| Earning Date | 04-29-2026 | 04-27-2026 |
| Dividend Yield | N/A | ★ 0.48% |
| EPS Growth | N/A | ★ 37.34 |
| EPS | N/A | ★ 11.63 |
| Revenue | $507,442,000.00 | ★ $17,364,829,000.00 |
| Revenue This Year | $23.32 | $7.67 |
| Revenue Next Year | $27.43 | $4.99 |
| P/E Ratio | ★ N/A | $14.67 |
| Revenue Growth | ★ 32.33 | 9.71 |
| 52 Week Low | $73.16 | $140.08 |
| 52 Week High | $191.62 | $246.33 |
| Indicator | GKOS | UHS |
|---|---|---|
| Relative Strength Index (RSI) | 55.85 | 52.15 |
| Support Level | $175.04 | $164.90 |
| Resistance Level | $184.00 | $176.99 |
| Average True Range (ATR) | 5.63 | 4.54 |
| MACD | -1.97 | -1.25 |
| Stochastic Oscillator | 30.42 | 31.31 |
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.
Universal Health Services Inc offers healthcare services through its behavioral health centers, acute care hospitals, and related outpatient facilities. As of late 2025, the company operated 346 inpatient behavioral health centers, 29 acute care hospitals, and many supportive outpatient facilities. Its operations are concentrated in the U.S, particularly in Nevada (21% of 2025 operating profits), Texas (19%), and California (13%), although it does have some exposure to the UK behavioral health market (6% of 2025 sales) too. While its acute care services account for over 55% of revenue, the behavioral health centers sport higher margins and account for over 55% of pretax profits.